Latest blog articles

  • Is ‘MOCCA’ in class 30 generic in China?

    What does the term ‘MOCCA’ evoke in your mind, a kind of coffee or a specific brand? This Kat randomly asked this question to her friends currently at the Max Planck Institute for Innovation and Competition Munich. Most of them regarded ‘MOCCA’ as a kind of coffee instead of a specific brand except...

    law_mocca_blog_tian_lu
  • Patent Aggregation in the Great White North

    Patent aggregation is one of the critical paths to raise revenue and earn a return on investment in the ICT sector. It comprises all activities whereby firms build sets of related patents, so-called patent portfolios, and subsequently use these beyond manufacturing. Different kinds of entities...

    law_patent_aggregation_in_the_great_white_north_blog_igir
  • The regulation of child influencers: A profitable playground

    Over the few past years, there has been a professionalization of social media content creators. These creators now have the power to sway their followers, start trends, or serve as role models for their audiences. These individuals, that have such online persuasive power, are called “influencers”...

    law_the regulation of child influencers
  • Consumers and businesses in digital markets – An unequal relationship?

    On 15 October, the Swedish Consumer Agency, its Scientific Council and Maastricht University (in particular the Law & Tech Lab) hosted the webinar 'Consumers and businesses in digital markets – An unequal relationship?’, focused on bringing together the perspectives of national consumer authorities...

    Consumers and businesses in digital markets - An unequal relationship?
  • Patent (f)laws and the front runners of COVID cure

    The ongoing COVID-19 pandemic is arguably one of the biggest crises of modern times. The conflict between the search for a vaccine, and the artificial scarcity created by patent law, has created a catch-22 situation. How will patent law apply to a vaccine under these circumstances?

    law_corona_vaccin_patent_blog